Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 ...

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Ex-Meta and DeepMind researchers raised $650m at a $4.65bn valuation for Recursive Superintelligence, a startup betting AI can automate its own research.

A2Z Cust2Mate Solutions Corp. (AZ) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.19 per share a year ago.

Wondering whether Recursion Pharmaceuticals at around US$3.39 is a bargain or a value trap? This article focuses squarely on what the current share price might be telling you about the business. The ...

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...

Part II asks what happens when we carry that insight forward — into the relationship between human minds and artificial ...

Richard Socher launched Recursive Superintelligence, a $650 million San Francisco startup building self-improving AI that ...

ADMA Biologics lowered its 2026 revenue guidance after reporting flat first-quarter sales and intensified competition in the ...

Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...